Newly approved drug effective against lung cancer caused by genetic mutation

The new drug sotorasib reduces tumor size and shows promise in improving survival among patients with lung tumors caused by a specific DNA mutation, according to results of a global phase 2 clinical trial. The drug is designed to shut down the effects of the mutation, which is found in about 13% of patients with lung adenocarcinoma, a common type of non-small-cell lung cancer.

Share:

Facebook
Twitter
Pinterest
LinkedIn

Leave a Reply

Related Posts

Vitamins and Minerals

Vitamins and minerals are micronutrients required by the body to carry out a range of normal functions. However, these micronutrients are not produced in our